Zacks Investment Research lowered shares of Urogen Pharma (NASDAQ:URGN) from a buy rating to a hold rating in a research report sent to investors on Thursday morning, Zacks.com reports.

According to Zacks, “UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company’s product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra’anana, Israel. “

URGN has been the topic of a number of other research reports. HC Wainwright initiated coverage on Urogen Pharma in a research report on Tuesday, January 29th. They issued a buy rating and a $82.00 target price on the stock. Raymond James set a $57.00 target price on Urogen Pharma and gave the company a buy rating in a research report on Friday, March 1st. Oppenheimer set a $70.00 target price on Urogen Pharma and gave the company a buy rating in a research report on Thursday, February 28th. Stifel Nicolaus restated a buy rating and issued a $63.00 target price on shares of Urogen Pharma in a research report on Tuesday, March 5th. Finally, Cowen restated a buy rating on shares of Urogen Pharma in a research report on Monday, May 6th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Urogen Pharma presently has an average rating of Buy and a consensus target price of $64.17.

NASDAQ:URGN opened at $38.28 on Thursday. Urogen Pharma has a 52 week low of $34.61 and a 52 week high of $69.57. The firm has a market capitalization of $526.39 million, a price-to-earnings ratio of -7.98 and a beta of 1.33.

Urogen Pharma (NASDAQ:URGN) last posted its earnings results on Thursday, May 9th. The company reported ($1.11) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.12) by $0.01. Urogen Pharma had a negative return on equity of 61.24% and a negative net margin of 4,296.08%. As a group, equities research analysts expect that Urogen Pharma will post -5.41 EPS for the current fiscal year.

In related news, insider Mark Schoenberg sold 1,991 shares of the business’s stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $37.30, for a total value of $74,264.30. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 10.50% of the stock is currently owned by insiders.

Hedge funds have recently bought and sold shares of the stock. Public Employees Retirement Association of Colorado purchased a new stake in shares of Urogen Pharma in the 1st quarter valued at $41,000. Parallel Advisors LLC raised its holdings in shares of Urogen Pharma by 100.0% in the 4th quarter. Parallel Advisors LLC now owns 1,000 shares of the company’s stock valued at $43,000 after buying an additional 500 shares during the period. Harel Insurance Investments & Financial Services Ltd. raised its holdings in shares of Urogen Pharma by 100.0% in the 1st quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,000 shares of the company’s stock valued at $74,000 after buying an additional 1,000 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Urogen Pharma by 112.6% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,421 shares of the company’s stock valued at $89,000 after buying an additional 1,282 shares during the period. Finally, Van ECK Associates Corp raised its holdings in shares of Urogen Pharma by 27.6% in the 4th quarter. Van ECK Associates Corp now owns 4,364 shares of the company’s stock valued at $188,000 after buying an additional 944 shares during the period. Hedge funds and other institutional investors own 72.78% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.

Further Reading: No Load Funds

Get a free copy of the Zacks research report on Urogen Pharma (URGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Urogen Pharma (NASDAQ:URGN)

Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.